Health News

New Skin Cancer Rx Gets Green Light
On July 24, 2015, the U. S. Food and Drug Administration approved sonidegib (Odomzo Capsules, Novartis Pharmaceuticals Corporation) for the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Sunglasses: Looking Cooler and Staying Healthier
Sunglasses can do more than make you look like a movie star — they can also help protect your eyes from the sun's harmful rays.
Indoor Tanning Fades, but Millions Still Risk It
At one time, many people thought indoor tanning meant a healthy glow year-round. Today, more and more people may be realizing that this isn’t so.
ED Rx: A Possible Downside
While medications for erectile dysfunction can improve men's lives, they may also carry a downside.
Do Sunscreen Labels Have You Confused?
Sunscreen and outdoor activities go hand-in-hand, especially in the summer. But when it comes to choosing a sunscreen, many people may be left in the dark.
Melanoma Rates on the Rise
After a long winter, you may be itching to head to the pool and bake in the sun. But don't grab your towel and sunglasses just yet. You may want to stay aware of the potential risks.
New Numbers on America's Most Common Cancer
The sun's rays may give you that healthy glow — but below the surface, there may be serious health risks.
Some Skin Cancers Saw Spike
As awareness about the dangers of sun exposure and skin cancer rises, the hope is that skin cancer rates will decrease. New evidence, however, suggests that rates may not be on the decline.
Melanoma on Downswing in Kids
Parents, you can breathe a sigh of relief — the sunscreen must be working. Melanoma, an aggressive form of skin cancer, appears to be decreasing in kids.
Bristol-Myers Squibb and Lilly Colaborate to Evaluate Cancer Drug
NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) announced today a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in combination with Lilly's galunisertib (LY2157299).